Talee Bio Inc., a Philadelphia biopharmaceutical company developing gene therapy treatments for cystic fibrosis, received a grant of up to $4.5 million from the Cystic Fibrosis Foundation.
The funds will be used by Talee Bio to fund the preclinical development of two gene therapy product candidates. The company has set a goal of initiating clinical trials for the first one in 2020.
The foundation has previously supported the company's product development efforts, which Talee Bio said is the result of decades of research by scientists developing innovations aimed at overcoming historical hurdles in treating a diseased lung. The company was founded by researchers from the University of Iowa and the Children’s Hospital of Philadelphia and Philadelphia-based Militia Hill Ventures, with support from Emily’s Entourage.
Click here to view the full story.
